APA (7th ed.) Citation

M, G., Y, X., L, A., Y, M., C, B., K, T., . . . HC, K. (2025). RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination. Communications biology, 9(1), 6. https://doi.org/10.1038/s42003-025-09223-0

Chicago Style (17th ed.) Citation

M, Gruet, et al. "RAS/PI3K Pathway Mutations Sensitise Epithelial Ovarian Cancer Cells to a PARP/NAMPT Inhibitor Combination." Communications Biology 9, no. 1 (2025): 6. https://doi.org/10.1038/s42003-025-09223-0.

MLA (9th ed.) Citation

M, Gruet, et al. "RAS/PI3K Pathway Mutations Sensitise Epithelial Ovarian Cancer Cells to a PARP/NAMPT Inhibitor Combination." Communications Biology, vol. 9, no. 1, 2025, p. 6, https://doi.org/10.1038/s42003-025-09223-0.